Bgm (BGM) Non-Current Assets (2019 - 2025)
Bgm's (BGM) quarterly Non-Current Assets came in at $382.3 million in Q3 2025, up 21911.37% year-on-year from N/an in Q3 2024, and up 132.45% on a QoQ basis from $164.5 million in Q1 2025.
Bgm (BGM) Non-Current Assets (2019 - 2025) Analysis & Trends
Bgm (BGM) has 7 years of Non-Current Assets data on file, last reported at $382.3 million in Q3 2025.
- On a quarterly basis, Non-Current Assets rose 21911.37% year-over-year to $382.3 million in Q3 2025; TTM through Sep 2025 was -$27078.7 billion, a 1559220761.62% decrease from a year earlier, with the FY2025 full-year figure at $382.3 million, up 21911.37% from the prior year.
- Non-Current Assets for Q3 2025 stood at $382.3 million, up from $164.5 million in the prior quarter.
- Over the last five years, Non-Current Assets for BGM reached as high as $382.3 million in Q3 2025 and fell as low as -$58505.6 billion in Q1 2021.
- Historically, Non-Current Assets has averaged -$12852.1 billion across 5 years, with a median of $9.1 million in 2024.
- Across the five-year window, Non-Current Assets plunged 95.69% in 2023 and soared 21911.37% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $35.0 million in 2021, then decreased by 1.42% to $34.5 million in 2022, then plunged by 95.69% to $1.5 million in 2023, then increased by 16.88% to $1.7 million in 2024, then surged by 21911.37% to $382.3 million in 2025.
- Per Business Quant data, the three most recent Non-Current Assets figures were $382.3 million in Q3 2025, $164.5 million in Q1 2025, and $1.7 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 3.84 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 18.82 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Bgm | 33.55 Mn | 23.73 Mn | - | 382.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 382.27 Mn |
| Mar 31, 2025 | 164.45 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Mar 31, 2024 | 16.53 Mn |
| Sep 30, 2023 | 1.49 Mn |
| Mar 31, 2023 | -27,079.30 Bn |
| Sep 30, 2022 | 34.49 Mn |
| Mar 31, 2022 | -42,936.45 Bn |
| Sep 30, 2021 | 34.99 Mn |
| Mar 31, 2021 | -58,505.61 Bn |
| Sep 30, 2020 | 10.63 Mn |
| Sep 30, 2019 | 10.30 Mn |